Ophthalmology · 2003
Treatment of ocular inflammatory disorders with daclizumab.
Клиническое исследованиеОценочное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Papaliodis George N, Chu David, Foster C Stephen
Аннотация
PURPOSE: To evaluate the efficacy and safety of daclizumab therapy for patients with various ophthalmologic inflammatory disorders (all having previously failed standard treatment methods).
DESIGN: Retrospective, nonrandomized case series.
PARTICIPANTS: Fourteen patients.
METHODS: Fourteen patients were treated with daclizumab after previously failing standard treatment methods.
MAIN OUTCOME MEASURES: Inflammation and visual acuity.
RESULTS: Twelve of 27 (44%) eyes and 5 of 14 (36%) patients had improvement in visual acuity; 9 of 27 (33%) eyes and 5 of 14 (36%) patients had no change in visual acuity; and 6 of 27 (22%) eyes and 4 of 14 (27%) patients had continued visual loss. Based on degree of inflammation, 16 of 27 eyes (59%) had improvement, 3 of 27 (11%) eyes had no change, and 8 of 27 (30%) eyes worsened.
CONCLUSIONS: Daclizumab is safe and, at least in some patients, appears to be an effective medication in the treatment of ocular inflammatory disorders.
DESIGN: Retrospective, nonrandomized case series.
PARTICIPANTS: Fourteen patients.
METHODS: Fourteen patients were treated with daclizumab after previously failing standard treatment methods.
MAIN OUTCOME MEASURES: Inflammation and visual acuity.
RESULTS: Twelve of 27 (44%) eyes and 5 of 14 (36%) patients had improvement in visual acuity; 9 of 27 (33%) eyes and 5 of 14 (36%) patients had no change in visual acuity; and 6 of 27 (22%) eyes and 4 of 14 (27%) patients had continued visual loss. Based on degree of inflammation, 16 of 27 eyes (59%) had improvement, 3 of 27 (11%) eyes had no change, and 8 of 27 (30%) eyes worsened.
CONCLUSIONS: Daclizumab is safe and, at least in some patients, appears to be an effective medication in the treatment of ocular inflammatory disorders.